Cabaletta Bio Inc. (NASDAQ:CABA) marked $8.77 per share on Friday, down from a previous closing price of $10.21. While Cabaletta Bio Inc. has underperformed by -14.10%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CABA rose by 131.40%, with highs and lows ranging from $10.87 to $0.59, whereas the simple moving average jumped by 297.33% in the last 200 days.
On August 30, 2022, Morgan Stanley Downgraded Cabaletta Bio Inc. (NASDAQ: CABA) to Equal-Weight. A report published by Wells Fargo on December 08, 2021, Initiated its previous ‘Overweight’ rating for CABA. Morgan Stanley also rated CABA shares as ‘Overweight’, setting a target price of $20 on the company’s shares in an initiating report dated October 19, 2021. Mizuho Initiated an Buy rating on June 30, 2021, and assigned a price target of $22. Chardan Capital Markets initiated its ‘Buy’ rating for CABA, as published in its report on January 08, 2021. H.C. Wainwright’s report from October 13, 2020 suggests a price prediction of $20 for CABA shares, giving the stock a ‘Buy’ rating. Morgan Stanley also rated the stock as ‘Overweight’.
Analysis of Cabaletta Bio Inc. (CABA)
In order to gain a clear picture of Cabaletta Bio Inc.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -50.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 15.20, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.40M can be a very valuable indicator of volatility for CABA stock. On a monthly basis, the volatility of the stock is set at 17.68%, whereas on a weekly basis, it is put at 15.97%, with a loss of -5.39% over the past seven days. Furthermore, long-term investors anticipate a median target price of $9.00, showing growth from the present price of $8.77, which can serve as yet another indication of whether CABA is worth investing in or should be passed over.
How Do You Analyze Cabaletta Bio Inc. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.10%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 42.30% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in CABA shares?
The recent increase in stakes in CABA appears to be a result of several institutional investors and hedge funds increasing their positions. During the last quarter, the company picked up 2,360,312 additional shares for a total stake of worth $10.57 million, bringing number of shares owned by the company to 2,360,312.
During the first quarter, Cormorant Asset Management LP added a 845,576 position in CABA. The Vanguard Group, Inc. purchased an additional 0.23 million shares in the last quarter, increasing its holdings by 21.65%, now holding 1.27 million shares worth $5.71 million. CABA shares are owned by institutional investors to the tune of 42.30% at present.